London, Sept 26 : A new study has revealed that women with advanced breast cancer can live longer by taking the drug Herceptin, even after they have suffered a relapse.
The finding is based on data from the Hermine trial, an observational study involving 340 women with advanced HER2-positive breast cancer.
Herceptin is the only HER2-targeted therapy proven to extend lives in both early and advanced stages of the disease.